Three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, have been widely used as first-line treatments for patients with HR-positive/HER2-negative breast cancer (Guo et al., 2023; Elfgen and Bjelic-Radisic, 2021). Here, CDK4 is linked to breast carcinoma.